These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 39072326)

  • 1. Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.
    Jiménez-Cabello L; Utrilla-Trigo S; Calvo-Pinilla E; Lorenzo G; Illescas-Amo M; Benavides J; Moreno S; Marín-López A; Nogales A; Ortego J
    Front Immunol; 2024; 15():1440407. PubMed ID: 39072326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2
    Utrilla-Trigo S; Jiménez-Cabello L; Calvo-Pinilla E; Marín-López A; Lorenzo G; Sánchez-Cordón P; Moreno S; Benavides J; Gilbert S; Nogales A; Ortego J
    J Virol; 2022 Feb; 96(3):e0161421. PubMed ID: 34787454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus.
    Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Benavente J; Brun A; Martínez-Costas JM; Ortego J
    Antiviral Res; 2017 Jun; 142():55-62. PubMed ID: 28322923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice.
    Marín-López A; Otero-Romero I; de la Poza F; Menaya-Vargas R; Calvo-Pinilla E; Benavente J; Martínez-Costas JM; Ortego J
    Antiviral Res; 2014 Oct; 110():42-51. PubMed ID: 25057758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR
    Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Brun A; Anguita J; Ortego J
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus.
    Calvo-Pinilla E; Navasa N; Anguita J; Ortego J
    PLoS One; 2012; 7(4):e34735. PubMed ID: 22514660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of Recombinant Modified Vaccinia Virus Ankara Encoding VP2, NS1, and VP7 Proteins of Bluetongue Virus.
    Marín-López A; Ortego J
    Methods Mol Biol; 2016; 1349():137-50. PubMed ID: 26458834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.
    Kochinger S; Renevey N; Hofmann MA; Zimmer G
    Vet Res; 2014 Jun; 45(1):64. PubMed ID: 24928313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.
    Calvo-Pinilla E; Rodríguez-Calvo T; Sevilla N; Ortego J
    Vaccine; 2009 Dec; 28(2):437-45. PubMed ID: 19857449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of VP7, a Bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep.
    Bouet-Cararo C; Contreras V; Caruso A; Top S; Szelechowski M; Bergeron C; Viarouge C; Desprat A; Relmy A; Guibert JM; Dubois E; Thiery R; Bréard E; Bertagnoli S; Richardson J; Foucras G; Meyer G; Schwartz-Cornil I; Zientara S; Klonjkowski B
    PLoS One; 2014; 9(11):e111605. PubMed ID: 25364822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of a conserved region of bluetongue virus protein VP2 in cross-neutralisation of bluetongue virus serotypes.
    Jyothi SJ; Patil SR; Reddy NY; Panduranga RP; Madala U; Prakash GM; Putty K
    Onderstepoort J Vet Res; 2020 Oct; 87(1):e1-e6. PubMed ID: 33054261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Comtet L; Lövgren Bengtsson K; Pringle J; Zientara S; Valarcher JF
    Clin Vaccine Immunol; 2013 Aug; 20(8):1115-22. PubMed ID: 23720365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
    Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
    Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Modified Vaccinia Virus Ankara Development to Express VP2, NS1, and VP7 Proteins of Bluetongue Virus.
    Marín-López A; Utrilla-Trigo S; Jiménez-Cabello L; Ortego J
    Methods Mol Biol; 2022; 2465():177-193. PubMed ID: 35118622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
    Feenstra F; van Gennip RGP; Maris-Veldhuis M; Verheij E; van Rijn PA
    J Gen Virol; 2014 Sep; 95(Pt 9):2019-2029. PubMed ID: 24914064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant bluetongue virus with hemagglutinin epitopes in VP2 has potential as a labeled vaccine.
    Guo Y; Huang L; Bi K; Xu Q; Bu Z; Wang F; Sun E
    Vet Microbiol; 2020 Sep; 248():108825. PubMed ID: 32891953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.